EIF2AK2 and pulmonary venoocclusive disease: The simultaneous treatment with the PKR antagonist C16 or the ISR inhibitor ISRIB, alongside MMC, prevents the impairment of pulmonary endothelial cells and the development of PVOD phenotypes (12).